IP Library › Granted Patent US 12,514,633
Granted Patent B2
US 12,514,633 · App. 18/051,356 · Granted Jan 6, 2026

Vessel modification using heat therapy

Inventors: Christopher P. Hartman (Rohnert Park, CA); Stefan S. Tunev (Santa Rosa, CA); Carlos H. Lima (Santa Rosa, CA); Richard J. Bliss (Cloverdale, CA)
Assignee: Medtronic Vascular, Inc.
A61B18/1492A61B2018/0022A61B2018/00285A61B2018/00345A61B2018/00577A61B2018/00672A61B2018/00678A61B2018/00714A61B2218/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,633
App. No.
18/051,356
Granted
Jan 6, 2026
Kind
B2
Abstract

A system includes an intravascular medical device and a therapeutic medical device. The intravascular medical device includes a heat therapy assembly and an elongated member coupled to the heat therapy assembly. The heat therapy assembly is configured to contract a wall of a vessel and deliver energy to the wall of the contracted vessel to heat the wall of the vessel. The therapeutic medical device is communicatively coupled to the heat therapy assembly and configured to control the heat therapy assembly to deliver the energy to ablate smooth muscle cells of the wall of the vessel and substantially denature one or more structural proteins of the wall of the vessel.

Claims (60)

1 . A system, comprising:

an intravascular medical device comprising:

a heat therapy assembly configured to:

contract a wall of a vessel adjacent to a treatment site to a reduced diameter; and

deliver energy to the wall of the contracted vessel to heat the wall of the vessel; and

an elongated member coupled to the heat therapy assembly; and

a therapeutic medical device communicatively coupled to the heat therapy assembly and configured to control the heat therapy assembly to deliver the energy to:

ablate smooth muscle cells of the wall of the vessel; and

substantially denature one or more structural proteins of the wall of the vessel,

wherein, to contract the wall of the vessel, the heat therapy assembly comprises a contraction assembly configured to isolate a constriction volume of the vessel adjacent to the treatment site and create a vacuum in the constriction volume.

2 . The system of claim 1 , wherein the contraction assembly comprises:

a proximal balloon configured to inflate to seal a proximal end of the constriction volume; and

a distal balloon configured to inflate to seal a distal end of the constriction volume.

3 . The system of claim 1 , wherein the heat therapy assembly includes one or more openings configured to remove a fluid from the constriction volume to create the vacuum.

4 . The system of claim 1 ,

wherein the heat therapy assembly comprises a balloon comprising a cavity configured to contain a thermal medium, the balloon defining one or more surfaces configured to contact the wall of the vessel, and

wherein the one or more surfaces are configured to deliver the energy from the thermal medium to the wall of the vessel.

5 . The system of claim 1 , wherein the heat therapy assembly comprises one or more therapeutic elements configured to deliver the energy to the wall of the vessel.

6 . The system of claim 1 ,

wherein the heat therapy assembly comprises an expansion device,

wherein the expansion device is configured to radially expand to expand the wall of the vessel, and

wherein the therapeutic medical device is configured to control the expansion device to expand the wall of the vessel to a particular diameter.

7 . The system of claim 1 ,

wherein the one or more structural proteins comprise elastin and collagen, and

wherein after substantial denaturation, the one or more structural proteins cross-link to form a scaffold.

8 . The system of claim 7 , wherein greater than about 50% of structural proteins at the treatment site are denatured.

9 . The system of claim 1 , wherein, to ablate the smooth muscle cells and substantially denature the one or more structural proteins, the therapeutic medical device is configured to control the heat therapy assembly to maintain a temperature of the smooth muscle cells within a target temperature range.

10 . The system of claim 9 ,

wherein the target temperature range is defined by a lower temperature threshold value associated with death of the smooth muscle cells and denaturation of the one or more structural proteins, and

wherein the lower temperature threshold value is greater than about 60° C.

11 . The system of claim 9 ,

wherein the target temperature range is defined by an upper temperature threshold value associated with bubble formation of one or more fluids in the wall of the vessel, and

wherein the upper temperature threshold is less than about 100° C.

12 . The system of claim 1 , wherein the contraction assembly comprises a vacuum balloon configured to deflate in the constriction volume to create the vacuum.

13 . The system of claim 12 , wherein the vacuum balloon is configured to deliver the energy to the wall of the vessel.

14 . A method comprising:

contracting a wall of a vessel adjacent to a treatment site to a reduced diameter, wherein the wall of the vessel includes smooth muscle cells and one or more structural proteins; and

heating the wall of the contracted vessel to ablate the smooth muscle cells and substantially denature the one or more structural proteins,

wherein contracting the wall of the vessel comprises sealing a constriction volume of the vessel adjacent to the treatment site and creating a vacuum in the constriction volume.

15 . The method of claim 14 ,

wherein the one or more structural proteins comprise elastin and collagen, and

wherein after substantial denaturation, the one or more structural proteins cross-link to form a scaffold.

16 . The method of claim 14 , wherein sealing the constriction volume comprises:

inflating a proximal balloon to seal a proximal end of the constriction volume; and

inflating a distal balloon to seal a distal end of the constriction volume.

17 . The method of claim 14 , wherein contracting the wall of the vessel further comprises removing a fluid from the constriction volume to create the vacuum.

18 . The system of claim 5 ,

wherein the one or more therapeutic elements comprise at least one thermoelectric element,

wherein the therapeutic medical device is configured to control an electrical current to at least one thermoelectric element, and

wherein at least one thermoelectric element comprises a plurality of Peltier devices.

19 . The method of claim 14 , wherein, to ablate the smooth muscle cells and substantially denature the one or more structural proteins, the method includes controlling a heat therapy assembly to maintain a temperature of the smooth muscle cells within a target temperature range.

20 . The method of claim 19 ,

wherein the target temperature range is defined by a lower temperature threshold value associated with death of the smooth muscle cells and denaturation of the one or more structural proteins, and

wherein the lower temperature threshold value is greater than about 60° C.

21 . The method of claim 19 ,

wherein the target temperature range is defined by an upper temperature threshold value associated with boiling of one or more fluids in the wall of the vessel, and

wherein the upper temperature threshold is less than about 100° C.

22 . The method of claim 14 ,

wherein creating the vacuum comprises deflating a vacuum balloon in the constriction volume.

23 . The method of claim 22 , wherein delivering energy to the wall of the vessel comprises delivering energy to the wall of the vessel from the vacuum balloon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: HARTMAN, CHRISTOPHER P.; TUNEV, STEFAN S.; LIMA, CARLOS H.; BLISS, RICHARD J.
To: MEDTRONIC VASCULAR, INC.
Reel/Frame 061818/0849 →
Continuity (2)
Provisional Application 63284414 · Nov 30, 2021
Related Publication 20230165633A1 · Jun 1, 2023
References Cited (25)
US 6080171A · Keith et al. · 2000 [cited by applicant]
US 6939345B2 · KenKnight et al. · 2005 [cited by applicant]
US 7344490B2 · Shaw et al. · 2008 [cited by applicant]
US 8048067B2 · Davalos et al. · 2011 [cited by applicant]
US 8911430B2 · Joey et al. · 2014 [cited by applicant]
US 9598691B2 · Davalos · 2017 [cited by applicant]
US 9615878B2 · Nair · 2017 [cited by applicant]
US 9999461B2 · Azamian et al. · 2018 [cited by applicant]
US 10085802B2 · Neuberger · 2018 [cited by applicant]
US 20020173784A1 · Sliwa et al. · 2002 [cited by applicant]
US 20110257641A1 · Hastings et al. · 2011 [cited by applicant]
US 20120065554A1 · Pikus · 2012 [cited by applicant]
US 20130190748A1 · Coe et al. · 2013 [cited by applicant]
US 20130197555A1 · Schaer · 2013 [cited by examiner]
US 20150282858A1 · Baust · 2015 [cited by examiner]
US 20160317625A1 · Dicosmo · 2016 [cited by examiner]
US 20180353239A1 · Stone et al. · 2018 [cited by applicant]
US 20190117301A1 · Steinke et al. · 2019 [cited by applicant]
US 20190224484A1 · Pierce et al. · 2019 [cited by applicant]
US 20200015886A1 · Whayne et al. · 2020 [cited by applicant]
US 20200179045A1 · Levin et al. · 2020 [cited by applicant]
WO 2017040371A1 · 2017 [cited by applicant]
Qiao et al., “Can Interventional Ablation be Applied to the Treatment of Arterial Aneurysm?,” Medical Hypotheses, vol. 80, No. 4, Apr. 2013, pp. 373-375. [cited by applicant]
U.S. Appl. No. 18/051,272, filed Oct. 31, 2022, naming inventors Hartman et al. [cited by applicant]
U.S. Appl. No. 18/051,310, filed Oct. 31, 2022, naming inventors Tunev et al. [cited by applicant]